Pipeline Exploring the future of precision nuclear medicine
We are advancing a diverse pipeline of innovative radiopharmaceuticals designed to address unmet patient needs across multiple disease areas. Guided by science and clinical insight, our focus is on developing next-generation solutions that improve patient outcomes.
Current Pipeline
Cu 64 PSMA I&T
PSMA
Cu-64 (Copper-64)
Prostate Cancer
Solar-Recur
NCT06235099
This is a prospective, open-label Phase 3 study evaluating copper Cu 64 zadavotide guraxetan (Cu 64 PSMA I&T) for the imaging of prostate cancer.
A Multi-Center, Open-Label, Randomized Phase study of Cu 64 PSMA I&T in patients with histologically proven prostate cancer.
To investigate the safety, tolerability, and efficacy of Cu 64 PSMA I&T in adult patients with prostate cancer.
Cu 64 PSMA I&T
PSMA
Cu-64 (Copper-64)
Prostate Cancer
Solar-Stage
NCT06235100
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 zadavotide guraxetan (Cu 64 PSMA I&T) in patients with prostate cancer.
A Multi-Center, Open-Label, Randomized Phase study of Cu 64 PSMA I&T in patients with histologically proven prostate cancer.
To investigate the safety, tolerability, and efficacy of Cu 64 PSMA I&T in adult patients with prostate cancer.
Ga 68 – ABS011
HER2
Ga-68 (Gallium-68)
Breast Cancer
Hermia
NCT06369831
Ga-68-labelled PET tracer targeting HER2, developed for non-invasive imaging of HER2 expression and patient selection/characterisation in oncology.
Phase 2b ABS-011 Ga-68 HER2 trial
To non-invasively image and assess HER2 expression in tumours using Ga-68 PET, supporting the identification and characterisation of patients with HER2-positive cancer.
Lu 177 PSMA I&T
PSMA
Lu-177 (Lutietium-177)
Prostate Cancer
Eclipse
NCT07771010
This is a prospective, open-label Phase 3 study to evaluate lutetium Lu 177 zadavotide guraxetan (Lu 177 PSMA I&T) for metastatic prostate cancer.
A Multi-Center, Open-Label, Randomized Phase study of Lu 177 PSMA I&T in patients with histologically proven prostate cancer.
To investigate the safety, tolerability, and efficacy of Lu 177 PSMA I&T in adult patients with prostate cancer.